Cargando…
Gracillin shows potent efficacy against colorectal cancer through inhibiting the STAT3 pathway
Colorectal cancer (CRC) accounts for about 10% of all annually diagnosed cancers and cancer‐related deaths worldwide. STAT3 plays a vital role in the occurrence and development of tumours. Gracillin has shown a significant antitumour activity in tumours, but its mechanism remains unknown. The human...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812262/ https://www.ncbi.nlm.nih.gov/pubmed/33259114 http://dx.doi.org/10.1111/jcmm.16134 |
_version_ | 1783637633043267584 |
---|---|
author | Yang, Lehe Zhu, Tianru Ye, Hua Shen, Yili Li, Zhiping Chen, Luye Wang, Canwei Chen, Xia Zhao, Haiyang Xiang, Youqun Xiao, Zhongxiang Zhao, Chengguang Li, Jifa Hu, Wanle |
author_facet | Yang, Lehe Zhu, Tianru Ye, Hua Shen, Yili Li, Zhiping Chen, Luye Wang, Canwei Chen, Xia Zhao, Haiyang Xiang, Youqun Xiao, Zhongxiang Zhao, Chengguang Li, Jifa Hu, Wanle |
author_sort | Yang, Lehe |
collection | PubMed |
description | Colorectal cancer (CRC) accounts for about 10% of all annually diagnosed cancers and cancer‐related deaths worldwide. STAT3 plays a vital role in the occurrence and development of tumours. Gracillin has shown a significant antitumour activity in tumours, but its mechanism remains unknown. The human CRC cell lines HCT116, RKO, and SW480 and immunodeficient mice were used as models to study the effects of gracillin on cell proliferation, migration and apoptosis. These were evaluated by cell viability, colony formation, wound‐healing migration and cell apoptosis assays. Luciferase reporter assay, and immunostaining and western blot analyses were used to explore the specific mechanism through which gracillin exerts its effects. Gracillin significantly reduces viability and migration and stimulates apoptosis in human CRC cells. It also significantly inhibits tumour growth with no apparent physiological toxicity in animal model experiments. Moreover, gracillin is found to inhibit STAT3 phosphorylation and STAT3 target gene products. In addition, gracillin inhibits IL6‐induced nuclear translocation of P‐STAT3. Gracillin shows potent efficacy against CRC by inhibiting the STAT3 pathway. It should be further explored as a unique STAT3 inhibitor for the treatment of CRC. |
format | Online Article Text |
id | pubmed-7812262 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78122622021-01-22 Gracillin shows potent efficacy against colorectal cancer through inhibiting the STAT3 pathway Yang, Lehe Zhu, Tianru Ye, Hua Shen, Yili Li, Zhiping Chen, Luye Wang, Canwei Chen, Xia Zhao, Haiyang Xiang, Youqun Xiao, Zhongxiang Zhao, Chengguang Li, Jifa Hu, Wanle J Cell Mol Med Original Articles Colorectal cancer (CRC) accounts for about 10% of all annually diagnosed cancers and cancer‐related deaths worldwide. STAT3 plays a vital role in the occurrence and development of tumours. Gracillin has shown a significant antitumour activity in tumours, but its mechanism remains unknown. The human CRC cell lines HCT116, RKO, and SW480 and immunodeficient mice were used as models to study the effects of gracillin on cell proliferation, migration and apoptosis. These were evaluated by cell viability, colony formation, wound‐healing migration and cell apoptosis assays. Luciferase reporter assay, and immunostaining and western blot analyses were used to explore the specific mechanism through which gracillin exerts its effects. Gracillin significantly reduces viability and migration and stimulates apoptosis in human CRC cells. It also significantly inhibits tumour growth with no apparent physiological toxicity in animal model experiments. Moreover, gracillin is found to inhibit STAT3 phosphorylation and STAT3 target gene products. In addition, gracillin inhibits IL6‐induced nuclear translocation of P‐STAT3. Gracillin shows potent efficacy against CRC by inhibiting the STAT3 pathway. It should be further explored as a unique STAT3 inhibitor for the treatment of CRC. John Wiley and Sons Inc. 2020-12-01 2021-01 /pmc/articles/PMC7812262/ /pubmed/33259114 http://dx.doi.org/10.1111/jcmm.16134 Text en © 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Yang, Lehe Zhu, Tianru Ye, Hua Shen, Yili Li, Zhiping Chen, Luye Wang, Canwei Chen, Xia Zhao, Haiyang Xiang, Youqun Xiao, Zhongxiang Zhao, Chengguang Li, Jifa Hu, Wanle Gracillin shows potent efficacy against colorectal cancer through inhibiting the STAT3 pathway |
title | Gracillin shows potent efficacy against colorectal cancer through inhibiting the STAT3 pathway |
title_full | Gracillin shows potent efficacy against colorectal cancer through inhibiting the STAT3 pathway |
title_fullStr | Gracillin shows potent efficacy against colorectal cancer through inhibiting the STAT3 pathway |
title_full_unstemmed | Gracillin shows potent efficacy against colorectal cancer through inhibiting the STAT3 pathway |
title_short | Gracillin shows potent efficacy against colorectal cancer through inhibiting the STAT3 pathway |
title_sort | gracillin shows potent efficacy against colorectal cancer through inhibiting the stat3 pathway |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812262/ https://www.ncbi.nlm.nih.gov/pubmed/33259114 http://dx.doi.org/10.1111/jcmm.16134 |
work_keys_str_mv | AT yanglehe gracillinshowspotentefficacyagainstcolorectalcancerthroughinhibitingthestat3pathway AT zhutianru gracillinshowspotentefficacyagainstcolorectalcancerthroughinhibitingthestat3pathway AT yehua gracillinshowspotentefficacyagainstcolorectalcancerthroughinhibitingthestat3pathway AT shenyili gracillinshowspotentefficacyagainstcolorectalcancerthroughinhibitingthestat3pathway AT lizhiping gracillinshowspotentefficacyagainstcolorectalcancerthroughinhibitingthestat3pathway AT chenluye gracillinshowspotentefficacyagainstcolorectalcancerthroughinhibitingthestat3pathway AT wangcanwei gracillinshowspotentefficacyagainstcolorectalcancerthroughinhibitingthestat3pathway AT chenxia gracillinshowspotentefficacyagainstcolorectalcancerthroughinhibitingthestat3pathway AT zhaohaiyang gracillinshowspotentefficacyagainstcolorectalcancerthroughinhibitingthestat3pathway AT xiangyouqun gracillinshowspotentefficacyagainstcolorectalcancerthroughinhibitingthestat3pathway AT xiaozhongxiang gracillinshowspotentefficacyagainstcolorectalcancerthroughinhibitingthestat3pathway AT zhaochengguang gracillinshowspotentefficacyagainstcolorectalcancerthroughinhibitingthestat3pathway AT lijifa gracillinshowspotentefficacyagainstcolorectalcancerthroughinhibitingthestat3pathway AT huwanle gracillinshowspotentefficacyagainstcolorectalcancerthroughinhibitingthestat3pathway |